Related Experiment Video
Updated: Aug 6, 2026
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
RBCK1 promotes chemotherapy resistance in bladder carcinoma by targeting HLTF
Xin Yang1, Zexian Ding2, Ya Pengwang1
1Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China; Department of Oncology, Guilin Hospital of The Second Xiangya Hospital, Central South University, Guilin, Guangxi 541100, China.
Pathology, Research and Practice
|July 18, 2026
Summary
Researchers identified a new pathway involving RBCK1, HLTF, and JAK2/STAT3 that drives cisplatin resistance in bladder cancer. Targeting this axis may improve chemotherapy effectiveness for patients.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Cisplatin resistance is a major challenge in bladder cancer treatment.
- E3 ubiquitin ligases are implicated in drug resistance, but their specific roles in bladder cancer are unclear.
Purpose of the Study:
- Identify E3 ubiquitin ligases driving cisplatin resistance in bladder cancer.
- Elucidate the molecular mechanisms underlying this resistance.
Main Methods:
- Integrated analysis of public transcriptomic datasets.
- Functional assays in bladder cancer cells (clonogenic survival, drug sensitivity).
- Protein interaction and degradation studies (ubiquitin-proteasome system).
- Western blotting and rescue experiments.
- In vivo xenograft models.
Main Results:
- RBCK1, an E3 ubiquitin ligase, is upregulated in bladder cancer and promotes cisplatin resistance.
- RBCK1 degrades HLTF, leading to JAK2/STAT3 pathway activation.
- HLTF loss exacerbates cisplatin resistance, while STAT3 inhibition reverses it.
- RBCK1 depletion enhances cisplatin response in vivo.
Conclusions:
- A novel RBCK1-HLTF-JAK2/STAT3 regulatory axis promotes cisplatin resistance in bladder cancer.
- Targeting RBCK1 or the JAK2/STAT3 pathway may overcome cisplatin resistance.
- Further clinical studies are needed to validate these findings for therapeutic application.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:20The Retinoblastoma Gene
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...